Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
52 Results for "
HLA-DR
" in MedChemExpress (MCE) Product Catalog:
Products (52)
52 Results for "HLA-DR" in MCE Product Catalog:
1
1
1 Cited Publications
Cat. No.: HY-P85898
Synonyms: CD 74 antibody; CD74 antibody; CD74 antigen; invariant polypeptide of major histocompatibility complex; class II antigen-associated; antibody; CD74 antigen antibody; CD74 molecule antibody; CD74 molecule; major histocompatibility complex; class II invariant chain antibody; CLIP antibody; DHLAG antibody; Gamma chain of class II antigens antibody; HG2A_HUMAN antibody; HLA class II histocompatibility antigen gamma chain antibody; HLA DR antigens associated invariant chain antibody; HLA DR gamma antibody; HLA-DR antigens-associated invariant chain antibody; HLA-DR-gamma antibody; HLADG antibody; HLADR antigens associated invariant chain antibody; Ia antigen associated invariant chain antibody; Ia antigen-associated invariant chain antibody; Ia associated invariant chain antibody; Ia gamma antibody; Ii antibody; Invariant polypeptide of major histocompatibility complex class II antigen associated antibody; la-gamma antibody; Major histocompatibility complex class II invariant chain antibody; MHC HLA DR gamma chain antibody; MHC HLA-DR gamma chain antibody; p33 antibody; p35 antibody; Protein 41 antibody;
Cat. No.: HY-P11303
CAS No.: 161147-59-7
연구분야:
Cat. No.: HY-P990189
Synonyms: N-Vanillylarachidonamide
Arvanil (N-Vanillylarachidonamide) is a mixed agonist of CB1 and TRPV1 receptors. Arvanil downregulates CD25, HLA-DR, CD134/OX40, blocks G1/S phase transition, and induces phosphorylation of Akt. Arvanil does not induce apoptosis in cells. Arvanil inhibits lymphocyte activation and ameliorates autoimmune encephalomyelitis. Arvanil can be used in research related to Huntington's disease, vomiting, and multiple sclerosis .
Cat. No.: HY-N10116A
CAS No.: 483-77-2
Category:
Cat. No.: HY-P2514
CAS No.: 410527-75-2
Target:
TET 830 modified/T-helper epitope from tetanus toxoid is a modified T-helper epitope peptide and an HLA-DR/MHC class II-restricted tetanus helper epitope. TET 830 modified/T-helper epitope from tetanus toxoid is used in the research of melanoma and ovarian cancer .
Target:
1-Adamantaneethanol is an allele-selective MHC II class molecule loading enhancer (MHC loading enhancer, MLE) that enhances peptide loading and ligand exchange of HLA-DR molecules. 1-Adamantaneethanol targets the polymorphic P1 pocket of HLA-DR molecules and preferentially acts on HLA-DR subtypes with Gly at position β86, thereby stabilizing the peptide-receptor conformation and accelerating antigen loading. 1-Adamantaneethanol can be used in studies related to MHC II antigen presentation, peptide vaccines, adaptive immunity and tumor immunity .
Cat. No.: HY-P5898
CAS No.: 155026-49-6
Synonyms: Z-Val-Val-Nle-CHN2
연구분야:
Cat. No.: HY-150749A
Purity: 99.82%
ODN D-SL03 sodium is a C class CpG oligonucleotides, and can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 sodium can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 sodium also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
Cat. No.: HY-P3248
CAS No.: 444305-16-2
Synonyms: Myelin basic protein (85-99) antagonist
Target:
연구분야:
Cat. No.: HY-P991750
Target:
연구분야:
Cat. No.: HY-159123
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
Cat. No.: HY-P10835
Cat. No.: HY-P2507
CAS No.: 508230-31-7
Target:
연구분야:
Cat. No.: HY-P1901
CAS No.: 872036-64-1
Target:
연구분야:
Cat. No.: HY-150740
Target:
연구분야:
ODN 21595 is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 reduces the expression of CD86 and HLA-DR. ODN 21595 has the potential for the research of systemic lupus erythematosus (SLE) .
Cat. No.: HY-150740A
Target:
연구분야:
ODN 21595 sodium is a Guanine-Modified TLR7 and TLR9 inhibitor. ODN 21595 sodium inhibits the release of IFN-α and IL-6 with no cytotoxic. ODN 21595 sodium reduces the expression of CD86 and HLA-DR. ODN 21595 sodium has the potential for the research of systemic lupus erythematosus (SLE) .
Cat. No.: HY-P991366
Synonyms: AL008
Cat. No.: HY-150749
CAS No.: 1198621-85-0
Target:
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3' .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
